EP2780082A4 - COMPOSITION AND METHOD FOR THE TREATMENT OF MORBUS ALZHEIMER - Google Patents
COMPOSITION AND METHOD FOR THE TREATMENT OF MORBUS ALZHEIMERInfo
- Publication number
- EP2780082A4 EP2780082A4 EP12847618.1A EP12847618A EP2780082A4 EP 2780082 A4 EP2780082 A4 EP 2780082A4 EP 12847618 A EP12847618 A EP 12847618A EP 2780082 A4 EP2780082 A4 EP 2780082A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- disease
- compositions
- methods
- treating alzheimer
- alzheimer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Psychiatry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161558430P | 2011-11-10 | 2011-11-10 | |
US201261589809P | 2012-01-23 | 2012-01-23 | |
US201213582308A | 2012-08-31 | 2012-08-31 | |
PCT/US2012/064722 WO2013071267A1 (en) | 2011-11-10 | 2012-11-12 | Compositions and methods for treating alzheimer's disease |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2780082A1 EP2780082A1 (en) | 2014-09-24 |
EP2780082A4 true EP2780082A4 (en) | 2015-08-05 |
Family
ID=48290671
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP12847618.1A Withdrawn EP2780082A4 (en) | 2011-11-10 | 2012-11-12 | COMPOSITION AND METHOD FOR THE TREATMENT OF MORBUS ALZHEIMER |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP2780082A4 (ru) |
CN (1) | CN104093454A (ru) |
AU (1) | AU2012335014A1 (ru) |
CA (1) | CA2855669A1 (ru) |
EA (1) | EA201491851A1 (ru) |
HK (1) | HK1201771A1 (ru) |
SG (1) | SG11201403272YA (ru) |
WO (1) | WO2013071267A1 (ru) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112012022229A2 (pt) | 2010-03-03 | 2016-07-05 | Univ British Columbia | epítopo beta amilóide epecíficio para oligômero e anticorpos |
EP3102611A4 (en) * | 2014-02-03 | 2017-08-23 | Cangene Corporation | Humanized beta-amyloid binding molecules and uses thereof |
WO2016008047A1 (en) * | 2014-07-14 | 2016-01-21 | Cangene Corporation | Cyclic peptide vaccination for treatment of amyloid beta-related disorders |
WO2016187339A1 (en) * | 2015-05-18 | 2016-11-24 | Synaptec Development Llc | GALANTAMINE CLEARANCE OF AMYLOIDß |
WO2017079833A1 (en) * | 2015-11-09 | 2017-05-18 | The University Of British Columbia | Epitopes in amyloid beta mid-region and conformationally-selective antibodies thereto |
EP3374382A4 (en) * | 2015-11-09 | 2019-05-15 | The University Of British Columbia | BETA-AMYLOID EPITOPES AND ASSOCIATED SELECTIVE CONFORMATIONAL ANTIBODIES |
US20180346534A1 (en) * | 2015-11-09 | 2018-12-06 | The University Of British Columbia | C-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto |
EP3374383A4 (en) * | 2015-11-09 | 2019-05-15 | The University Of British Columbia | BETA-AMYLOID EPITOPES AND ASSOCIATED ANTIBODIES |
WO2017079831A1 (en) | 2015-11-09 | 2017-05-18 | The University Of British Columbia | N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto |
US20180125920A1 (en) | 2016-11-09 | 2018-05-10 | The University Of British Columbia | Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions |
US10259865B2 (en) * | 2017-03-15 | 2019-04-16 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
CN112661828B (zh) * | 2021-01-15 | 2022-04-01 | 武汉大学 | 一种突触素的抗原肽及其抗体与应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010002251A1 (en) * | 2008-07-01 | 2010-01-07 | De Staat Der Nederlanden, Vert. Door De Minister Van Vws | Vaccine against amyloid folding intermediate |
WO2011106885A1 (en) * | 2010-03-03 | 2011-09-09 | The University Of British Columbia | Oligomer-specific amyloid beta epitope and antibodies |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110306605A1 (en) * | 2008-12-22 | 2011-12-15 | Sloan-Kettering Institute For Cancer Research | Coumarin-based compounds for the treatment of alzheimer's disease and cancer |
WO2011100292A1 (en) * | 2010-02-09 | 2011-08-18 | Bristol-Myers Squibb Company | Immunoassay standards and measurement of clinical biomarkers using intra-assay calibration standards |
-
2012
- 2012-11-12 EP EP12847618.1A patent/EP2780082A4/en not_active Withdrawn
- 2012-11-12 CN CN201280066632.7A patent/CN104093454A/zh active Pending
- 2012-11-12 WO PCT/US2012/064722 patent/WO2013071267A1/en active Application Filing
- 2012-11-12 EA EA201491851A patent/EA201491851A1/ru unknown
- 2012-11-12 SG SG11201403272YA patent/SG11201403272YA/en unknown
- 2012-11-12 AU AU2012335014A patent/AU2012335014A1/en not_active Abandoned
- 2012-11-12 CA CA2855669A patent/CA2855669A1/en not_active Abandoned
-
2015
- 2015-03-05 HK HK15102253.1A patent/HK1201771A1/xx unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010002251A1 (en) * | 2008-07-01 | 2010-01-07 | De Staat Der Nederlanden, Vert. Door De Minister Van Vws | Vaccine against amyloid folding intermediate |
WO2011106885A1 (en) * | 2010-03-03 | 2011-09-09 | The University Of British Columbia | Oligomer-specific amyloid beta epitope and antibodies |
Non-Patent Citations (4)
Title |
---|
BRIAN O'NUALLAIN ET AL: "Human Plasma Contains Cross-Reactive A[beta] Conformer-Specific IgG Antibodies +", BIOCHEMISTRY, vol. 47, no. 47, 25 November 2008 (2008-11-25), pages 12254 - 12256, XP055198127, ISSN: 0006-2960, DOI: 10.1021/bi801767k * |
MAGGA JOHANNA ET AL: "Human intravenous immunoglobulin provides protection against AÎ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease", JOURNAL OF NEUROINFLAMMATION, BIOMED CENTRAL LTD., LONDON, GB, vol. 7, no. 1, 7 December 2010 (2010-12-07), pages 90, XP021089590, ISSN: 1742-2094, DOI: 10.1186/1742-2094-7-90 * |
MICHELA ROSINI ET AL: "Inhibition of Acetylcholinesterase, [beta]-Amyloid Aggregation, and NMDA Receptors in Alzheimer's Disease: A Promising Direction for the Multi-target-Directed Ligands Gold Rush", JOURNAL OF MEDICINAL CHEMISTRY, vol. 51, no. 15, 1 August 2008 (2008-08-01), pages 4381 - 4384, XP055198095, ISSN: 0022-2623, DOI: 10.1021/jm800577j * |
See also references of WO2013071267A1 * |
Also Published As
Publication number | Publication date |
---|---|
EP2780082A1 (en) | 2014-09-24 |
AU2012335014A1 (en) | 2014-06-19 |
CA2855669A1 (en) | 2013-05-16 |
SG11201403272YA (en) | 2014-08-28 |
EA201491851A1 (ru) | 2015-12-30 |
HK1201771A1 (en) | 2015-09-11 |
CN104093454A (zh) | 2014-10-08 |
WO2013071267A1 (en) | 2013-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2707369A4 (en) | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | |
HRP20182069T1 (hr) | Farmaceutski pripravci za liječenje alzheimerove bolesti | |
ZA201406209B (en) | Methods and compositions for treating huntington's disease | |
SG11201403272YA (en) | Compositions and methods for treating alzheimer's disease | |
HK1202416A1 (en) | Compositions and methods for preventing and treating oral diseases | |
IL236054A0 (en) | Compositions and methods for treating Crohn's disease and related conditions and infections | |
EP2684167A4 (en) | COMPOSITIONS AND METHODS USEFUL IN THE TREATMENT OF DISEASES | |
EP2655334A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES | |
HK1246660A1 (zh) | 用於治療阿爾茨海默病的方法和藥物產品 | |
EP2542255A4 (en) | METHOD AND COMPOSITIONS FOR TREATING THE DEGOS SYNDROME | |
DK3292875T3 (en) | Compositions and methods for treating diseases | |
EP2691529A4 (en) | METHOD AND COMPOSITIONS FOR TREATING BRAIN DISEASES | |
EP2485733A4 (en) | METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
HRP20180687T1 (hr) | Kompozicije i metode za liječenje celijakije spru | |
HK1202248A1 (en) | Compositions and methods for treating neurodegenerative disease | |
HK1202246A1 (en) | Compositions and methods for treating neurodegenerative disease | |
EP2866894A4 (en) | COMPOSITION AND METHOD FOR THE TREATMENT OF MORBUS ALZHEIMER | |
EP2667896A4 (en) | METHOD AND COMPOSITION FOR TREATING MORBUS ALZHEIMER | |
EP2906225A4 (en) | METHODS OF TREATING KENNEDY'S DISEASE | |
EP2693877A4 (en) | METHODS AND COMPOSITIONS FOR TREATING RAYNAUD'S DISEASE | |
EP2829605A4 (en) | PROCESS FOR SCREENING THERAPEUTIC AND / OR PROPHYLACTICS FOR MORBUS ALZHEIMER | |
ZA201402477B (en) | Compounds for use in the treatment of alzheimer's disease | |
IL214340A0 (en) | Methods and compositions for treating alzheimer's disease | |
EP2892618A4 (en) | METHOD FOR SELECTIVELY INHIBITING THE ACTIVITY OF ACAT1 IN THE TREATMENT OF MORBUS ALZHEIMER |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20140602 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
RA4 | Supplementary search report drawn up and despatched (corrected) |
Effective date: 20150703 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: G01N 33/68 20060101ALI20150629BHEP Ipc: C07K 16/06 20060101AFI20150629BHEP Ipc: C07K 14/47 20060101ALI20150629BHEP Ipc: A61K 39/395 20060101ALI20150629BHEP Ipc: C07K 7/64 20060101ALI20150629BHEP Ipc: A61P 25/28 20060101ALI20150629BHEP |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1201771 Country of ref document: HK |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: MCCLARTY, GRANT Owner name: CANGENE U.S. INCORPORATED Owner name: THE UNIVERSITY OF BRITISH COLUMBIA Owner name: CASHMAN, NEIL R. Owner name: CANGENE CORPORATION |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: CNJ HOLDINGS INC. Owner name: THE UNIVERSITY OF BRITISH COLUMBIA |
|
17Q | First examination report despatched |
Effective date: 20170811 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20171222 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1201771 Country of ref document: HK |